The DOI matches its Crossref record; 166 of the 166 references it cites were found in a registry or an index.
The clinical development of histone deacetylase inhibitors as targeted anticancer drugs
Open accessAbstract
IMPORTANCE OF THE FIELD: Histone deacetylase (HDAC) inhibitors are being developed as a new, targeted class of anticancer drugs. AREA COVERED IN THIS REVIEW: This review focuses on the mechanisms of action of the HDAC inhibitors, which selectively induce cancer cell death. WHAT THE READER WILL GAIN: There are 11 zinc-dependent HDACs in humans and the biological roles of these lysine deacetylases are not completely understood. It is clear that these different HDACs are not redundant in their activity. This review focuses on the mechanisms by which HDAC inhibitors can induce transformed cell growth arrest and cell death, inhibit cell mobility and have antiangiogenesis activity. There are more than a dozen HDAC inhibitors, including hydroxamates, cyclic peptides, benzamides and fatty acids, in various stages of clinical trials and many more compounds in preclinical development. The chemically different HDAC inhibitors may target different HDACs. TAKE HOME MESSAGE: There are extensive preclinical studies with transformed cells in culture and tumor-bearing animal models, as well as limited clinical studies reported to date, which indicate that HDAC inhibitors will be most useful when used in combination with cytotoxic or other targeted anticancer agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Chen, C.-S., Wang, Y.-C., Yang, H.-C., Huang, P.-H., Kulp, S. K., Yang, C.-C., Lu, Y.-S., Matsuyama, S., Chen, C.-Y., & Chen, C.-S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3996 · Cited by 187
RetractedRosato, R. R., Maggio, S. C., Almenara, J. A., Payne, S. G., Atadja, P. W., Spiegel, S., Dent, P., & Grant, S. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.017145 · Cited by 91
RetractedJenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756 · cited 1×
“Patterns of acetylation and methylation of lysines, as well as other post-translational modifications, appear to be a code for specific recruitment of protein complexes regulating gene expression and DNA replication and stability [5].”
BackgroundJones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040 · cited 4×
“These sites were identified on proteins that regulate gene expression, RNA signaling, DNA damage repair, cell cycle progression, nuclear transport, cytoskeleton function, protein chaperones, and ribosome formation and function [7].”
BackgroundInfluentialThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Self-citationFunctions of Site-Specific Histone Acetylation and Deacetylation
Shahbazian, M. D., & Grunstein, M. (2007) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.76.052705.162114 · Cited by 1,635
Kawaguchi, Y., Kovacs, J. J., McLaurin, A., Vance, J. M., Ito, A., & Yao, T.-P. (2003) · Cell · doi:10.1016/s0092-8674(03)00939-5 · Cited by 1,524
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Cytochrome C -Mediated Apoptosis
Jiang, X., & Wang, X. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073706 · Cited by 1,357
Marks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,196
Self-citationHistone Deacetylase Inhibitors: Overview and Perspectives
Dokmanovic, M., Clarke, C., & Marks, P. A. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0324 · Cited by 1,164
Self-citationHDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid Receptor
Kovacs, J. J., Murphy, P. J. M., Gaillard, S., Zhao, X., Wu, J.-T., Nicchitta, C. V., Yoshida, M., Toft, D. O., Pratt, W. B., & Yao, T.-P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.021 · Cited by 1,153 · cited 2×
“7 Inhibition of HDAC6 and target proteins HDAC6 is unique among zinc-containing HDACs in having two catalytic sites: a ubiquitin binding site and cytoplasmic localization where it associates with non-histone substrates, such as HSP90 and a-tubulin [18-22,94-96].”
BackgroundRichon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090
Self-citationHaggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066
Kelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 905
Self-citationHockly, E., Richon, V. M., Woodman, B., Smith, D. L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., Lowden, P. A. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437870100 · Cited by 845
Self-citationEssential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression
Lagger, G., O'Carroll, D., Rembold, M., Khier, H., Tischler, J., Weitzer, G., Schuettengruber, B., Hauser, C., Brunmeir, R., Jenuwein, T., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/21.11.2672 · Cited by 760
Bali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500186200 · Cited by 755 · cited 2×
“Recent studies have demonstrated both a direct physical interaction between HDAC6 and HSP90 and HDAC6 as a regulator of HSP90 activity through its deacetylation [22,95-98].”
BackgroundPiekarz, R. L., Frye, R., Turner, M., Wright, J. J., Allen, S. L., Kirschbaum, M. H., Zain, J., Prince, H. M., Leonard, J. P., Geskin, L. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6150 · Cited by 740
Nishiyama, A., Matsui, M., Iwata, S., Hirota, K., Masutani, H., Nakamura, H., Takagi, Y., Sono, H., Gon, Y., & Yodoi, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21645 · Cited by 730
Thioredoxin and Related Molecules–From Biology to Health and Disease
Lillig, C. H., & Holmgren, A. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.9.25 · Cited by 724 · cited 1×
“6 ROS and altered redox pathways HDACi cause an accumulation of ROS in transformed cells but not in normal cells [55,56,89-91].”
BackgroundHDAC6 Modulates Cell Motility by Altering the Acetylation Level of Cortactin
Zhang, X., Yuan, Z., Zhang, Y., Yong, S., Salas-Burgos, A., Koomen, J., Olashaw, N., Parsons, J. T., Yang, X.-J., Dent, S. R., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.033 · Cited by 722
Histone deacetylase inhibitors: Potential in cancer therapy
Marks, P. A., & Xu, W. ‐. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22185 · Cited by 712
Self-citationHistone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility
Montgomery, R. L., Davis, C. A., Potthoff, M. J., Haberland, M., Fielitz, J., Qi, X., Hill, J. A., Richardson, J. A., & Olson, E. N. (2007) · Genes & Development · doi:10.1101/gad.1563807 · Cited by 712
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders
Kazantsev, A. G., & Thompson, L. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2681 · Cited by 711
Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases
Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) · Structure · doi:10.1016/j.str.2004.04.012 · Cited by 710 · cited 1×
“More recently, the crystal structure of human HDAC4, 7 and 8 have been solved [32-35].”
BackgroundMicroRNA-206 Delays ALS Progression and Promotes Regeneration of Neuromuscular Synapses in Mice
Williams, A. H., Valdez, G., Moresi, V., Qi, X., McAnally, J., Elliott, J. L., Bassel-Duby, R., Sanes, J. R., & Olson, E. N. (2009) · Science · doi:10.1126/science.1181046 · Cited by 673
(1996) · Europe PMC (PubMed Central) · Cited by 659
Vannini, A., Volpari, C., Filocamo, G., Casavola, E. C., Brunetti, M., Renzoni, D., Chakravarty, P., Paolini, C., De Francesco, R., Gallinari, P., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404603101 · Cited by 638
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors
Shao, Y., Gao, Z., Marks, P. A., & Jiang, X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408345102 · Cited by 605
Self-citationGui, C.-Y., Ngo, L., Xu, W. S., Richon, V. M., & Marks, P. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307708100 · Cited by 550
Self-citationPeart, M. J., Smyth, G. K., van Laar, R. K., Bowtell, D. D., Richon, V. M., Marks, P. A., Holloway, A. J., & Johnstone, R. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500369102 · Cited by 539
Self-citationMitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., Gu, X., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536759100 · Cited by 531
Self-citationInsinga, A., Monestiroli, S., Ronzoni, S., Gelmetti, V., Marchesi, F., Viale, A., Altucci, L., Nervi, C., Minucci, S., & Pelicci, P. G. (2005) · Nature Medicine · doi:10.1038/nm1160 · Cited by 516
Butler, L. M., Zhou, X., Xu, W.-S., Scher, H. I., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182372299 · Cited by 510
Self-citationUngerstedt, J. S., Sowa, Y., Xu, W.-S., Shao, Y., Dokmanovic, M., Perez, G., Ngo, L., Holmgren, A., Jiang, X., & Marks, P. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408732102 · Cited by 503
Self-citationMolecular mechanisms of leukemogenesis mediated by MLL fusion proteins
Ayton, P. M., & Cleary, M. L. (2001) · Oncogene · doi:10.1038/sj.onc.1204639 · Cited by 500
Ruefli, A. A., Ausserlechner, M. J., Bernhard, D., Sutton, V. R., Tainton, K. M., Kofler, R., Smyth, M. J., & Johnstone, R. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191208598 · Cited by 488
Epigenetics in cancer: Targeting chromatin modifications
Ellis, L., Atadja, P. W., & Johnstone, R. W. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0860 · Cited by 479
(2003) · PubMed · Cited by 465
Garcia-Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J., Wierda, W. G., Faderl, S., Koller, C., Morris, G., Rosner, G., et al. (2008) · Blood · doi:10.1182/blood-2007-06-098061 · Cited by 459
The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance
Villagra, A., Cheng, F., Wang, H.-W., Suarez, I., Glozak, M., Maurin, M., Nguyen, D., Wright, K. L., Atadja, P. W., Bhalla, K., et al. (2009) · Nature Immunology · doi:10.1038/ni.1673 · Cited by 455
Histone Deacetylase 7 Maintains Vascular Integrity by Repressing Matrix Metalloproteinase 10
Chang, S., Young, B. D., Li, S., Qi, X., Richardson, J. A., & Olson, E. N. (2006) · Cell · doi:10.1016/j.cell.2006.05.040 · Cited by 453
The role of the redox protein thioredoxin in cell growth and cancer
Powis, G., Mustacich, D., & Coon, A. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00313-0 · Cited by 443
Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
Atadja, P. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.019 · Cited by 419
O'Connor, O. A., Heaney, M. L., Schwartz, L., Richardson, S., Willim, R., MacGregor-Cortelli, B., Curly, T., Moskowitz, C., Portlock, C., Horwitz, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.9679 · Cited by 404
Self-citationBhaskara, S., Chyla, B. J., Amann, J. M., Knutson, S. K., Cortez, D., Sun, Z.-W., & Hiebert, S. W. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.02.030 · Cited by 372
Taddei, A., Maison, C., Roche, D., & Almouzni, G. (2001) · Nature Cell Biology · doi:10.1038/35055010 · Cited by 361
Galanis, E., Jaeckle, K. A., Maurer, M. J., Reid, J. M., Ames, M. M., Hardwick, J. S., Reilly, J. F., Loboda, A., Nebozhyn, M., Fantin, V. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.0694 · Cited by 358
Epigenetics and transgenerational transfer: a physiological perspective
Ho, D. H., & Burggren, W. W. (2010) · Journal of Experimental Biology · doi:10.1242/jeb.019752 · Cited by 353
Regulation of histone deacetylase activities
Sengupta, N., & Seto, E. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20179 · Cited by 346
Munshi, A., Kurland, J. F., Nishikawa, T., Tanaka, T., Hobbs, M. L., Tucker, S. L., Ismail, S., Stevens, C., & Meyn, R. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2088 · Cited by 345
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
Duvic, M., & Vu, J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.7.1111 · Cited by 344
Expression profile of class I histone deacetylases in human cancer tissues
Nakagawa, M., Oda, Y., Eguchi, T., Aishima, S.-I., Yao, T., Hosoi, F., Basaki, Y., Ono, M., Kuwano, M., Tanaka, M., et al. (2007) · Oncology Reports · doi:10.3892/or.18.4.769 · Cited by 341
Kelly, W. K., & Marks, P. A. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0106 · Cited by 330
Self-citationRunx2 (Cbfa1, AML-3) Interacts with Histone Deacetylase 6 and Represses the p21CIP1/WAF1 Promoter
Westendorf, J. J., Zaidi, S. K., Cascino, J. E., Kahler, R., van Wijnen, A. J., Lian, J. B., Yoshida, M., Stein, G. S., & Li, X. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.22.7982-7992.2002 · Cited by 324
HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation
Parmigiani, R. B., Xu, W. S., Venta-Perez, G., Erdjument-Bromage, H., Yaneva, M., Tempst, P., & Marks, P. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803749105 · Cited by 321
Self-citationBottomley, M. J., Lo Surdo, P., Di Giovine, P., Cirillo, A., Scarpelli, R., Ferrigno, F., Jones, P., Neddermann, P., De Francesco, R., Steinkühler, C., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803514200 · Cited by 312
Giles, F., Fischer, T., Cortes, J., Garcia-Manero, G., Beck, J., Ravandi, F., Masson, E., Rae, P., Laird, G., Sharma, S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0511 · Cited by 312
Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast*
Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Ando, Y., Mita, K., Hamaguchi, M., Hara, Y., Kobayashi, S., & Iwase, H. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-6001-1 · Cited by 305
Qian, D. Z., Kachhap, S. K., Collis, S. J., Verheul, H. M. W., Carducci, M. A., Atadja, P., & Pili, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4598 · Cited by 299
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition
Ropero, S., Fraga, M. F., Ballestar, E., Hamelin, R., Yamamoto, H., Boix-Chornet, M., Caballero, R., Alaminos, M., Setien, F., Paz, M. F., et al. (2006) · Nature Genetics · doi:10.1038/ng1773 · Cited by 290
Lin, H., Hu, C., Chan, H., Liew, Y., Huang, H., Lepescheux, L., Bastianelli, E., Baron, R., Rawadi, G., & Clément‐Lacroix, P. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707165 · Cited by 272
Nakata, S., Yoshida, T., Horinaka, M., Shiraishi, T., Wakada, M., & Sakai, T. (2004) · Oncogene · doi:10.1038/sj.onc.1207830 · Cited by 271
HDAC6–p97/VCP controlled polyubiquitin chain turnover
Boyault, C., Gilquin, B., Zhang, Y., Rybin, V., Garman, E., Meyer‐Klaucke, W., Matthias, P., Müller, C. W., & Khochbin, S. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601210 · Cited by 267
Kong, X., Lin, Z., Liang, D., Fath, D., Sang, N., & Caro, J. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2019-2028.2006 · Cited by 258
Zhao, Y., Tan, J., Zhuang, L., Jiang, X., Liu, E. T., & Yu, Q. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505585102 · Cited by 246
Steele, N. L., Plumb, J. A., Vidal, L., Tjørnelund, J., Knoblauch, P., Rasmussen, A., Ooi, C. E., Buhl-Jensen, P., Brown, R., Evans, T. R. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1786 · Cited by 244
Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression
Yang, X.-J., & Seto, E. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(03)00015-7 · Cited by 241
Shah, M. H., Binkley, P., Chan, K., Xiao, J., Arbogast, D., Collamore, M., Farra, Y., Young, D., & Grever, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2689 · Cited by 241
Luu, T. H., Morgan, R. J., Leong, L., Lim, D., McNamara, M., Portnow, J., Frankel, P., Smith, D. D., Doroshow, J. H., Gandara, D. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0122 · Cited by 237
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination
Adimoolam, S., Sirisawad, M., Chen, J., Thiemann, P., Ford, J. M., & Buggy, J. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707828104 · Cited by 236
Piekarz, R. L., Frye, A. R., Wright, J. J., Steinberg, S. M., Liewehr, D. J., Rosing, D. R., Sachdev, V., Fojo, T., & Bates, S. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2095 · Cited by 232
Targeting tumor angiogenesis with histone deacetylase inhibitors
Ellis, L., Hammers, H., & Pili, R. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.11.012 · Cited by 232
Chen, C.-S., Weng, S.-C., Tseng, P.-H., Lin, H.-P., & Chen, C.-S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505733200 · Cited by 231
Histone Deacetylase Inhibitors: Current Status and Overview of Recent Clinical Trials
Ma, X., Ezzeldin, H. H., & Diasio, R. B. (2009) · Drugs · doi:10.2165/11315680-000000000-00000 · Cited by 227
Brogdon, J. L., Xu, Y., Szabo, S. J., An, S., Buxton, F., Cohen, D., & Huang, Q. (2007) · Blood · doi:10.1182/blood-2006-04-019711 · Cited by 227
Modesitt, S. C., Sill, M., Hoffman, J. S., & Bender, D. P. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.01.009 · Cited by 225
Arts, J., King, P., Marin, A., Floren, W., Belin, A., Janssen, L., Pilatte, I., Roux, B., Decrane, L., Gilissen, R., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0547 · Cited by 224
Epigenetics: molecular mechanisms and implications for disease
Handel, A. E., Ebers, G. C., & Ramagopalan, S. V. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.11.003 · Cited by 222
Isoform-specific histone deacetylase inhibitors: The next step?
Balasubramanian, S., Verner, E., & Buggy, J. J. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.013 · Cited by 220
Enhancing the apoptotic and therapeutic effects of HDAC inhibitors
Frew, A. J., Johnstone, R. W., & Bolden, J. E. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.042 · Cited by 219
Munshi, A., Tanaka, T., Hobbs, M. L., Tucker, S. L., Richon, V. M., & Meyn, R. E. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0022 · Cited by 219
Rational Combinations Using HDAC Inhibitors
Bots, M., & Johnstone, R. W. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2786 · Cited by 217
HDAC inhibitors as anti‐inflammatory agents
Adcock, I. M. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707166 · Cited by 216
Gilbert, J., Baker, S. D., Bowling, M. K., Grochow, L. B., Figg, W. D., Zabelina, Y., Donehower, R. C., & Carducci, M. A. (2001) · PubMed · Cited by 206
Dowling, M. L., Voong, K. R., Kim, M., Keutmann, M. K., Harris, E., & Kao, G. D. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.2.1441 · Cited by 204
Carducci, M. A., Gilbert, J., Bowling, M. K., Noe, D. A., Eisenberger, M. A., Sinibaldi, V. J., Zabelina, Y., Chen, T., Grochow, L. B., & Donehower, R. C. (2001) · PubMed · Cited by 202
HDAC4 Regulates Neuronal Survival in Normal and Diseased Retinas
Chen, B., & Cepko, C. L. (2009) · Science · doi:10.1126/science.1166226 · Cited by 193
Ramalingam, S. S., Parise, R. A., Ramananthan, R. K., Lagattuta, T. F., Musguire, L. A., Stoller, R. G., Potter, D. M., Argiris, A. E., Zwiebel, J. A., Egorin, M. J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0162 · Cited by 193
Histone deacetylases and the immunological network: implications in cancer and inflammation
Villagra, A., Sotomayor, E. M., & Seto, E. (2010) · Oncogene · doi:10.1038/onc.2009.334 · Cited by 192
Zhang, X. D., Gillespie, S. K., Borrow, J. M., & Hersey, P. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.425.3.4 · Cited by 190
Atmaca, A., Al-Batran, S.-E., Maurer, A., Neumann, A., Heinzel, T., Hentsch, B., Schwarz, S. E., Hövelmann, S., Göttlicher, M., Knuth, A., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603851 · Cited by 183
Cimini, D., Mattiuzzo, M., Torosantucci, L., & Degrassi, F. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-01-0860 · Cited by 182
Xu, W., Ngo, L., Perez, G., Dokmanovic, M., & Marks, P. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607518103 · Cited by 179
Self-citationTranscriptional regulation in acute promyelocytic leukemia
Lin, R. J., Sternsdorf, T., Tini, M., & Evans, R. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204853 · Cited by 178
Crump, M., Coiffier, B., Jacobsen, E. D., Sun, L., Ricker, J. L., Xie, H., Frankel, S. R., Randolph, S. S., & Cheson, B. D. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn031 · Cited by 178
Vansteenkiste, J., Van Cutsem, E., Dumez, H., Chen, C., Ricker, J. L., Randolph, S. S., & Schöffski, P. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9131-6 · Cited by 174
Gore, L., Rothenberg, M. L., O'Bryant, C. L., Schultz, M. K., Sandler, A. B., Coffin, D., McCoy, C., Schott, A., Scholz, C., & Eckhardt, S. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1461 · Cited by 171
Hsp90: A Novel Target for Cancer Therapy
Solit, D., & Rosen, N. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606777812068 · Cited by 170
Development of vorinostat: Current applications and future perspectives for cancer therapy
Richon, V. M., Garcia-Vargas, J., & Hardwick, J. S. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.002 · Cited by 169
Blumenschein, G. R., Kies, M. S., Papadimitrakopoulou, V. A., Lu, C., Kumar, A. J., Ricker, J. L., Chiao, J. H., Chen, C., & Frankel, S. R. (2008) · Investigational New Drugs · doi:10.1007/s10637-007-9075-2 · Cited by 167
Two Catalytic Domains Are Required for Protein Deacetylation
Zhang, Y., Gilquin, B., Khochbin, S., & Matthias, P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c500241200 · Cited by 160
Ramalingam, S. S., Belani, C. P., Ruel, C., Frankel, P., Gitlitz, B., Koczywas, M., Espinoza-Delgado, I., & Gandara, D. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318191520c · Cited by 159
Woyach, J. A., Kloos, R. T., Ringel, M. D., Arbogast, D., Collamore, M., Zwiebel, J. A., Grever, M. R., Villalona-Calero, M. A., & Shah, M. H. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1631 · Cited by 156
Lee, S., Park, J., Seo, M., Roh, K., Park, S., Hwang, J., Sun, B., Seo, K., Lee, Y. ‐., Kang, S., et al. (2009) · Cell Proliferation · doi:10.1111/j.1365-2184.2009.00633.x · Cited by 154
Coffey, D. C., Kutko, M. C., Glick, R. D., Butler, L. M., Heller, G., Rifkind, R. A., Marks, P. A., Richon, V. M., & LaQuaglia, M. P. (2001) · PubMed · Cited by 154
Self-citationEpigenetic Modifiers: Basic Understanding and Clinical Development
Piekarz, R., & Bates, S. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2788 · Cited by 151
Rascle, A., Johnston, J. A., & Amati, B. B. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.12.4162-4173.2003 · Cited by 145
Histone deacetylase inhibitors specifically kill nonproliferating tumour cells
Burgess, A., Ruefli, A. A., Beamish, H., Warrener, R., Saunders, N. A., Johnstone, R. W., & Gabrielli, B. G. (2004) · Oncogene · doi:10.1038/sj.onc.1207893 · Cited by 144
Novotny‐Diermayr, V., Sangthongpitag, K., Hu, C. Y., Wu, X., Sausgruber, N., Yeo, P., Greicius, G., Pettersson, S., Liang, A. L., Loh, Y. K., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0689 · Cited by 141
Kummar, S., Gutierrez, M. E., Gardner, E. R., Donovan, E. A., Hwang, K., Chung, E. J., Lee, M.-J., Maynard, K., Kalnitskiy, M., Chen, A. P., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0791 · Cited by 140
Histone deacetylase inhibitors: insights into mechanisms of lethality
Rosato, R. R., & Grant, S. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.4.809 · Cited by 139
Histone deacetylase inhibitors and genomic instability
Éot-Houllier, G., Fulcrand, G., Magnaghi-Jaulin, L., & Jaulin, C. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.06.005 · Cited by 132
Wilson, A. J., Chüeh, A. C., Tögel, L., Corner, G. A., Ahmed, N., Goel, S., Byun, D.-S., Nasser, S., Houston, M. A., Jhawer, M. P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2327 · Cited by 127
Mechanisms of Resistance to Histone Deacetylase Inhibitors and Their Therapeutic Implications
Fantin, V. R., & Richon, V. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2114 · Cited by 127
Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients
Chang, H., Chiang, C., Hung, H.-C., Lin, C., Deng, Y., & Kuo, M. Y. (2008) · Oral Oncology · doi:10.1016/j.oraloncology.2008.08.011 · Cited by 126
Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin
Schrump, D. S., Fischette, M. R., Nguyen, D. M., Zhao, M., Li, X., Kunst, T. F., Hancox, A., Hong, J. A., Chen, G. A., Kruchin, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0135 · Cited by 126
Siu, L. L., Пили, Р., Durán, I., Messersmith, W. A., Chen, E. X., Sullivan, R., MacLean, M., King, S., Brown, S., Reid, G. K., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5730 · Cited by 125
Induction of Polyploidy by Histone Deacetylase Inhibitor: A Pathway for Antitumor Effects
Xu, W., Perez, G., Ngo, L., Gui, C.-Y., & Marks, P. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4608 · Cited by 121
Self-citationGaymes, T. J., Padua, R. A., Pla, M., Orr, S. J., Omidvar, N., Chomienne, C., Mufti, G. J., & Rassool, F. V. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0111 · Cited by 120
Chemical Origins of Isoform Selectivity in Histone Deacetylase Inhibitors
Kozikowski, A. P., & Butler, K. V. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208783885353 · Cited by 116
Golay, J., Cuppini, L., Leoni, F., Micò, M. C., Barbui, V., Domenghini, M., Lombardi, L. T., Neri, A., Barbui, A. M., Salvi, A., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404860 · Cited by 116
Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer
Botrugno, O. A., Santoro, F., & Minucci, S. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.027 · Cited by 114
Histone deacetylase inhibitors selectively suppress expression of HDAC7
Dokmanovic, M., Perez, G., Xu, W., Ngo, L., Clarke, C., Parmigiani, R. B., & Marks, P. A. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0251 · Cited by 106
Self-citationROBBINS, A. R., Jablonski, S. A., Yen, T. J., Yoda, K., Robey, R. W., Bates, S. E., & Sackett, D. L. (2005) · Cell Cycle · doi:10.4161/cc.4.5.1690 · Cited by 105
Increased expression of peroxiredoxin II confers resistance to cisplatin.
Chung, Y. M., Yoo, Y. D., Park, J. K., Kim, Y. T., & Kim, H. J. (2001) · PubMed · Cited by 98
Biomarkers for predicting clinical responses to HDAC inhibitors
Stimson, L., & Thangue, N. B. L. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.03.016 · Cited by 98
Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin
Schrump, D. S., Fischette, M. R., Nguyen, D. M., Zhao, M., Li, X., Kunst, T. F., Hancox, A., Hong, J. A., Chen, G. A., Kruchin, E., et al. (2007) · Clinical Lung Cancer · doi:10.1016/s1525-7304(11)70818-x · Cited by 97
Gloghini, A., Buglio, D., Khaskhely, N. M., Georgakis, G. V., Orlowski, R. Z., Neelapu, S. S., Carbone, A., & Younes, A. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07887.x · Cited by 96
Mahboobi, S., Dove, S., Sellmer, A., Winkler, M., Eichhorn, E., Pongratz, H., Ciossek, T., Baer, T., Maier, T. M., & Beckers, T. L. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800988r · Cited by 93
Effects of Histone Deacetylase Inhibitors on HIF-1
Liang, D., Kong, X., & Sang, N. (2006) · Cell Cycle · doi:10.4161/cc.5.21.3409 · Cited by 92
Phuphanich, S., Baker, S. D., Grossman, S. A., Carson, K. A., Gilbert, M. R., Fisher, J. D., & Carducci, M. A. (2005) · Neuro-Oncology · doi:10.1215/s1152851704000183 · Cited by 91
Gray, S. G., Qian, C., Furge, K., Guo, X., & Teh, B. T. (2004) · International Journal of Oncology · doi:10.3892/ijo.24.4.773 · Cited by 90
Targeting of HDAC8 and investigational inhibitors in neuroblastoma
Oehme, I., Deubzer, H. E., Lodrini, M., Milde, T., & Witt, O. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/14728220903241658 · Cited by 85
Nolan, L., Johnson, P., Ganesan, A., Packham, G., & Crabb, S. J. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604557 · Cited by 85
Targeting Histone Deacetylase Inhibitors for Anti-Malarial Therapy
Andrews, K. T., Tran, T., Wheatley, N. M., & Fairlie, D. P. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609788085313 · Cited by 83
Glucose Metabolism as a Target of Histone Deacetylase Inhibitors
Wardell, S. E., Ilkayeva, O., Wieman, H. L., Frigo, D. E., Rathmell, J. C., Newgard, C. B., & McDonnell, D. P. (2008) · Molecular Endocrinology · doi:10.1210/me.2008-0179 · Cited by 82
Fouladi, M., Furman, W. L., Chin, T. K., Freeman, B. B., Dudkin, L., Stewart, C. F., Krailo, M., Speights, R., Ingle, A. M., Houghton, P. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4964 · Cited by 82
Camacho, L. H., Olson, J., Tong, W. P., Young, C. W., Spriggs, D. R., & Malkin, M. G. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-9017-4 · Cited by 81
Marson, C. M. (2009) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152009788679976 · Cited by 81
Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Mai, A., Rotili, D., Valente, S., & Kazantsev, A. G. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789649349 · Cited by 80
Borbone, E., Berlingieri, M. T., Bellis, F. D., Nebbioso, A., Chiappetta, G., Mai, A., Altucci, L., & Fusco, A. (2009) · Oncogene · doi:10.1038/onc.2009.306 · Cited by 74
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
Marchion, D. C., Biçaku, E., Turner, J. G., Schmitt, M. L., Morelli, D., & Münster, P. N. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0985 · Cited by 73
Thioredoxin in cancer—Role of histone deacetylase inhibitors
Marks, P. A. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.09.005 · Cited by 72
Self-citationNovel Structural Insights into Class I and II Histone Deacetylases
Ficner, R. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609788085304 · Cited by 71
Watanabe, T., Kato, H., Kobayashi, Y., Yamasaki, S., Morita‐Hoshi, Y., Yokoyama, H., Morishima, Y., Ricker, J. L., Otsuki, T., Miyagi‐Maesima, A., et al. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01360.x · Cited by 69
Histone deacetylase inhibitors that target tubulin
Schemies, J., Sippl, W., & Jung, M. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.040 · Cited by 68
New patented histone deacetylase inhibitors
Wang, H., & Dymock, B. W. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903393789 · Cited by 65
Tan, J. Y., Zhuang, L., Jiang, X., Yang, K., Karuturi, K. M., & Yu, Q. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512719200 · Cited by 65
Shiozawa, K., Nakanishi, T., Tan, M., Fang, H.-B., Wang, W.-C., Edelman, M. J., Carlton, D., Gojo, I., Sausville, E. A., & Ross, D. D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1587 · Cited by 64
An (2009) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000204 · Cited by 58
Wang, L. G., Ossowski, L., & Ferrari, A. C. (2004) · Oncogene · doi:10.1038/sj.onc.1207654 · Cited by 51
Kano, Y., Akutsu, M., Tsunoda, S., Izumi, T., Kobayashi, H., Mano, H., & Furukawa, Y. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-9000-0 · Cited by 48
Pharmacological Modulation of Stem Cell Function
Romagnani, P., Lasagni, L., Mazzinghi, B., Lazzeri, E., & Romagnani, S. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707780362880 · Cited by 47
Fujiwara, Y., Yamamoto, N., Yamada, Y., Yamada, K., Otsuki, T., Kanazu, S., Iwasa, T., Hardwick, J. S., & Tamura, T. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01237.x · Cited by 46
Butt, M., Sailhamer, E. A., Li, Y., Liu, B., Shuja, F., Velmahos, G. C., DeMoya, M. A., King, D. R., & Alam, H. B. (2009) · Journal of Surgical Research · doi:10.1016/j.jss.2009.04.012 · Cited by 41
Linking histone deacetylation with the repair of DNA breaks
Fernández-Capetillo, Ó., & Nussenzweig, A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307342101 · Cited by 37
Kim, S., Kim, N. H., Lee, W., Seo, D. W., & Kim, Y. K. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0296 · Cited by 35
Varghese, S., Senanayake, T., Stewart, T. M., Doering, K., Fraser, A. V., Casero, R. A., & Woster, P. M. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701384x · Cited by 34
Cao, H., Jung, M., & Stamatoyannopoulos, G. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2005.08.007 · Cited by 22
Reid, T. R., Weeks, A., Vakil, M., Cosgriff, T. M., Harper, T., Valone, F. H., Magnuson, D., & Bhatnagar, A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.7279 · Cited by 16
Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma
Zain, J. M., Foss, F. M., Kelly, W. K., DeBono, J., Petrylak, D. P., Narwal, A., Neylon, E., Blumenschein, G. R., Lassen, U., & O’Connor, O. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.8580 · Cited by 16
Cited by
Epigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Khan, O., & La Thangue, N. B. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.100 · Cited by 450
“dtd"[ ]> Histone deacetylase (HDAC) inhibitors are a diverse group of small-molecule drugs that induce a broad range of effects on cancer cells, including cell cycle arrest, apoptosis, cell differentiation, autophagy and anti-angiogenic effects”
BackgroundHistone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy
Cao, D. J., Wang, Z. V., Battiprolu, P. K., Jiang, N., Morales, C. R., Kong, Y., Rothermel, B. A., Gillette, T. G., & Hill, J. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015081108 · Cited by 405
The epigenetics of aging and neurodegeneration
Lardenoije, R., Iatrou, A., Kenis, G., Kompotis, K., Steinbusch, H. W. M., Mastroeni, D., Coleman, P., Lemere, C. A., Hof, P. R., van den Hove, D. L. A., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.002 · Cited by 381
Nicotinamide Improves Aspects of Healthspan, but Not Lifespan, in Mice
Mitchell, S. J., Bernier, M., Aon, M. A., Cortassa, S., Kim, E. Y., Fang, E. F., Palacios, H. H., Ali, A., Navas-Enamorado, I., Di Francesco, A., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.001 · Cited by 338
Metadata
- Authors
- Marks, P. A.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2010-08-05
- Volume
- 19
- Issue
- 9
- Pages
- 1049-1066
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2014941193
- Cited by
- 281
- References
- 166
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.